Director, Marketing Strategy and Planning (HIV Treatment) at Gilead Sciences

Foster City, California, United States

Apply Now

Not SpecifiedCompensation

Senior (5 to 8 years), Expert & Leadership (9+ years)Experience Level

Full TimeJob Type

UnknownVisa

Pharmaceuticals, Healthcare, BiotechnologyIndustries

Requirements

A minimum of 5 years of brand development and marketing
Experience working on products within a portfolio (a plus)
Excellent strategic thinking skills with ability to formulate, develop and execute strategy
Ability to translate market research findings into actionable insights and tactical plans
Strong capacity to collaborate with and lead cross-functional teams, working cooperatively with commercial management, medical affairs, compliance, market research and others
Ability to understand and communicate clinical data and high-level science
Demonstrated excellence in project management and effectively managing multiple projects/priorities
Ability to effectively lead agencies and other external partners on strategic and tactical initiatives
Ensures compliance with all applicable laws, regulations and regulatory guidelines governing commercial and scientific interactions with healthcare professionals, payers, advocacy and other business partners

Responsibilities

Develop a bold vision for the launch of a novel oral therapy in HIV Treatment (BIC/LEN) and gain buy-in from cross-functional leaders
Effectively collaborate with internal partners to drive launch alignment and operational excellence
Support launch and strategic initiatives for BIC/LEN, a novel new HIV treatment
Collaborate with brand leadership and cross-functional team members to generate brand analytics and therapeutic insight generation (e.g., market size and dynamics, product clinical profile, product differentiation, competitive environment, market share trends, and lifecycle plans) to inform strategic brand direction
Lead launch planning cross-functional teams in the development of strategic and tactical plans supporting a new launch in HIV Treatment, including establishing governance standards, leading and coordinating cross-functional planning team, and ensuring launch planning timelines are developed, continuously assessed, and on time
Drive Strategic Brand Communications (coordinating between GCPS, Public Affairs)
Closely collaborate with the Global BIC/LEN Commercial team to ensure US strategy is aligned to Global Commercial Strategy

Skills

Marketing Strategy

Launch Planning

HIV Treatment

Cross-Functional Collaboration

Strategic Visioning

Bictegravir

Lenacapavir

Pharmaceutical Marketing

Gilead Sciences

Develops and commercializes biopharmaceuticals

About Gilead Sciences

Gilead Sciences focuses on discovering, developing, and commercializing medicines for various medical conditions, including HIV/AIDS, liver diseases, cancer, inflammatory and respiratory diseases, and cardiovascular issues. The company conducts extensive research and development to create new therapies, which are then marketed to healthcare providers, hospitals, and pharmacies after receiving regulatory approval. Gilead differentiates itself from competitors through its strong commitment to R&D and strategic partnerships, such as with SAP Ariba, to enhance its operations and product offerings. The company's goal is to improve health equity and access to care globally, working with communities to ensure that its medicines reach those in need.

Foster City, CaliforniaHeadquarters

1987Year Founded

$15,873.6MTotal Funding

IPOCompany Stage

Biotechnology, HealthcareIndustries

10,001+Employees

Benefits

Paid family time off and paid parental time off

Generous 401(k) contribution matching

Comprehensive medical plans that cover both physical and mental healthcare

Global Wellbeing Reimbursement

Time Off

Global Volunteer Day

Giving Together Program

Employee Support Programs

Flexible Work Options

Risks

Increased competition in HIV treatment from ViiV Healthcare's expanding drug portfolio.

Regulatory scrutiny over drug pricing could impact Gilead's U.S. market operations.

Patent expirations, like Truvada's, lead to increased generic competition and revenue loss.

Differentiation

Gilead's lenacapavir is recognized as the 2024 Breakthrough of the Year for HIV care.

Partnerships with LEO Pharma and Tubulis enhance Gilead's focus on inflammatory and cancer therapies.

Gilead's commitment to health equity initiatives like COMPASS and HepConnect sets it apart.

Upsides

Gilead's strategic partnerships expand its reach in inflammatory and oncology drug markets.

Investment in digital health technologies enhances Gilead's R&D and patient engagement.

Focus on sustainability improves Gilead's operational efficiency and corporate reputation.

Land your dream remote job 3x faster with AI

Try Jobo Free